Pylum Biosciences
David Martin has extensive experience in the biotechnology and pharmaceutical industries, currently serving as CEO of Pylum Biosciences, Inc. since December 2017 and as CEO of AvidBiotics Corp. since 2005. Previous leadership roles include CEO positions at Eos Biotechnology (1996-2003), Lynx, Inc. (1995-1996), and President at Chiron Therapeutics (1994-1995). Prior roles include Executive Vice President of Research and Development at DuPont-Merck (1991-1994) and Senior Vice President of Research and Development at Genentech (1983-1990). David Martin began a distinguished academic career as a Howard Hughes Investigator and Professor of Medicine and Biochemistry at UCSF Medical Center from 1969 to 1982. David Martin holds an MD from MIT and Duke Medical School, specializing in internal medicine and medical genetics.
This person is not in any teams
Pylum Biosciences
Pylum Biosicences offers an Avidocin platform technology capable of generating bactericidal protein complexes targeting specific bacterial pathogens. The Avidocin platform can be quickly modified to generate new protein complexes to kill emerging strains as their genome sequences become available. Avidocin proteins employ a unique killing mechanismthat is oblivious to the mechanisms bacteria have evolved to resist traditional antibiotics, and because of their tailorable specificity, they can be directed against specific species or strains with minimal or no off-target effects.The company currently has in development Avidocin agents targeting 10 different organisms including threatening human pathogens such as C. difficile, uropathogenic E. coli, and K. pneumonia. Pre-clinical animal studies have demonstrated that Avidocin proteins can be orally or parentally administered to prevent or treat disease with impressive efficacy in multiple infection models.